Comparative Cardiovascular Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors in Diabetes Mellitus
This large-scale, multi-national real-world study found that individual glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors exhibit broadly comparable cardiovascular effectiveness in patients with type 2 diabetes, supporting current treatment guidelines that prioritize individual patient factors over specific drug selection.